These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 18437041)

  • 1. Efficacy of disease-modifying therapies in relapsing remitting multiple sclerosis: a systematic comparison.
    Freedman MS; Hughes B; Mikol DD; Bennett R; Cuffel B; Divan V; LaVallee N; Al-Sabbagh A
    Eur Neurol; 2008; 60(1):1-11. PubMed ID: 18437041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A composite score to predict short-term disease activity in patients with relapsing-remitting MS.
    Sormani MP; Rovaris M; Comi G; Filippi M
    Neurology; 2007 Sep; 69(12):1230-5. PubMed ID: 17875911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis.
    Etemadifar M; Janghorbani M; Shaygannejad V
    Acta Neurol Scand; 2006 May; 113(5):283-7. PubMed ID: 16629762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
    Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
    Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regression of new gadolinium enhancing lesion activity in relapsing-remitting multiple sclerosis.
    Zhao Y; Traboulsee A; Petkau AJ; Li D
    Neurology; 2008 Mar; 70(13 Pt 2):1092-7. PubMed ID: 18003938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.
    Fazekas F; Lublin FD; Li D; Freedman MS; Hartung HP; Rieckmann P; Sørensen PS; Maas-Enriquez M; Sommerauer B; Hanna K; ;
    Neurology; 2008 Jul; 71(4):265-71. PubMed ID: 18645164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Long-term effects of glatiramer acetate in multiple sclerosis].
    Brochet B
    Rev Neurol (Paris); 2008 Nov; 164(11):917-26. PubMed ID: 18790510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis.
    Gajofatto A; Bacchetti P; Grimes B; High A; Waubant E
    Mult Scler; 2009 Jan; 15(1):50-8. PubMed ID: 18922831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
    Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current disease-modifying treatment of multiple sclerosis.
    Derwenskus J
    Mt Sinai J Med; 2011; 78(2):161-75. PubMed ID: 21425262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative study.
    Boster A; Hreha S; Berger JR; Bao F; Penmesta R; Tselis A; Endress C; Zak I; Perumal J; Caon C; Vazquez J; Tyler KL; Racke MK; Millis S; Khan O
    Arch Neurol; 2009 May; 66(5):593-9. PubMed ID: 19433659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The incomplete nature of multiple sclerosis relapse resolution.
    Lublin FD
    J Neurol Sci; 2007 May; 256 Suppl 1():S14-8. PubMed ID: 17337274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cost-utility analisys of multiple sclerosis treatment with glatiramer acetate or interferon beta in Spain].
    Rubio-Terrés C; Arístegui Ruiz I; Medina Redondo F; Izquierdo Ayuso G
    Farm Hosp; 2003; 27(3):159-65. PubMed ID: 12835817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.
    Havrdova E; Zivadinov R; Krasensky J; Dwyer MG; Novakova I; Dolezal O; Ticha V; Dusek L; Houzvickova E; Cox JL; Bergsland N; Hussein S; Svobodnik A; Seidl Z; Vaneckova M; Horakova D
    Mult Scler; 2009 Aug; 15(8):965-76. PubMed ID: 19465443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lessons from randomised direct comparative trials.
    Achiron A; Fredrikson S
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S19-24. PubMed ID: 19200860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach.
    Sormani MP; Bonzano L; Roccatagliata L; Cutter GR; Mancardi GL; Bruzzi P
    Ann Neurol; 2009 Mar; 65(3):268-75. PubMed ID: 19334061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current evidence and therapeutic strategies for multiple sclerosis.
    Wingerchuk DM
    Semin Neurol; 2008 Feb; 28(1):56-68. PubMed ID: 18256987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing disability progression with the Multiple Sclerosis Functional Composite.
    Rudick RA; Polman CH; Cohen JA; Walton MK; Miller AE; Confavreux C; Lublin FD; Hutchinson M; O'Connor PW; Schwid SR; Balcer LJ; Lynn F; Panzara MA; Sandrock AW
    Mult Scler; 2009 Aug; 15(8):984-97. PubMed ID: 19667023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A dose comparison study of IVIG in postpartum relapsing-remitting multiple sclerosis.
    Haas J; Hommes OR
    Mult Scler; 2007 Aug; 13(7):900-8. PubMed ID: 17881400
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.